We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+15.86%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$219M
AUM Growth
+$95.8M
(+78%)
Cap. Flow
+$80.7M
Cap. Flow
% of AUM
36.91%
Top 10 Holdings %
Top 10 Hldgs %
33.7%
Holding
163
New
55
Increased
48
Reduced
23
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco DB Commodity Index Tracking Fund
DBC
|
+$32.3M |
| 2 |
AJRD
Aerojet Rocketdyne Holdings
AJRD
|
+$3.42M |
| 3 |
TXNM
TXNM Energy Inc
TXNM
|
+$3.29M |
| 4 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$3.26M |
| 5 |
Indivior Pharmaceuticals
INDV
|
+$2.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$4.25M |
| 2 |
Coupang
CPNG
|
+$4.1M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
+$3.46M |
| 4 |
TGNA
TEGNA Inc
TGNA
|
+$2.44M |
| 5 |
First Horizon
FHN
|
+$2.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.57% |
| 2 | Technology | 13.44% |
| 3 | Communication Services | 5.29% |
| 4 | Consumer Discretionary | 4.52% |
| 5 | Financials | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.67B
| $32.6M | 14.92% |
1,436,136
+1,393,740
| +3,287% | +$32.3M |
|
2
MoonLake Immunotherapeutics
MLTX
$1.66B
| $6.62M | 3.03% |
129,722
+7,521
| +6% | +$202K |
|
|
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.49M | 2.51% |
139,552
+41,458
| +42% | +$1.46M |
|
|
ATVI
4
DELISTED
Activision Blizzard
ATVI
| $5.19M | 2.37% |
61,520
+21,520
| +54% | +$1.74M |
|
|
VMW
5
DELISTED
VMware, Inc
VMW
| $4.82M | 2.21% |
33,556
+9,956
| +42% | +$1.29M |
|
6
Albertsons Companies
ACI
$5.57B
| $4.12M | 1.88% |
188,753
+34,753
| +23% | +$723K |
|
7
Microsoft
MSFT
$2.89T
| $3.87M | 1.77% |
11,358
+7,718
| +212% | +$2.42M |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $3.71M | 1.7% |
338,842
-8,944
| -3% | -$83.3K |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.66M | 1.67% |
19,015
-2,933
| -13% | -$583K |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.6M | 1.64% |
34,954
+5,954
| +21% | +$628K |
|
|
BKI
11
DELISTED
Black Knight, Inc. Common Stock
BKI
| $3.59M | 1.64% |
60,121
+17,921
| +42% | +$1.01M |
|
12
Axsome Therapeutics
AXSM
$12.3B
| $3.55M | 1.62% |
49,400
-11,374
| -19% | -$839K |
|
|
MMP
13
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $3.49M | 1.59% |
+55,927
| New | +$3.26M |
|
14
Immunovant
IMVT
$8.23B
| $3.42M | 1.57% |
180,320
+16,521
| +10% | +$308K |
|
|
AJRD
15
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $3.38M | 1.54% |
+61,520
| New | +$3.42M |
|
|
TXNM
16
TXNM Energy Inc
TXNM
$6.44B
| $3.15M | 1.44% |
+69,909
| New | +$3.29M |
|
|
17
Indivior Pharmaceuticals
INDV
$4.73B
| $3.09M | 1.42% |
+130,000
| New | +$2.98M |
|
|
NUVL
18
DELISTED
Nuvalent
NUVL
| $3.05M | 1.39% |
72,298
+59,093
| +448% | +$2.23M |
|
19
Salesforce
CRM
$142B
| $2.97M | 1.36% |
14,079
+8,469
| +151% | +$1.73M |
|
|
KDNY
20
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.92M | 1.34% |
76,021
+26,526
| +54% | +$681K |
|
|
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
| $2.76M | 1.26% |
30,242
-8,869
| -23% | -$765K |
|
22
Alphabet (Google) Class C
GOOG
$3.99T
| $2.67M | 1.22% |
22,036
+13,536
| +159% | +$1.57M |
|
23
Immunocore
IMCR
$1.72B
| $2.64M | 1.21% |
44,094
+30,900
| +234% | +$1.76M |
|
24
Olema Pharmaceuticals
OLMA
$1.05B
| $2.64M | 1.21% |
+292,276
| New | +$1.76M |
|
25
Viridian Therapeutics
VRDN
$2.18B
| $2.59M | 1.18% |
108,765
+13,856
| +15% | +$355K |
|
Similar funds
SIAG
MS
WI
BHBT
WTFG
RC
VIA
A6
HighVista Strategies's Q2 2023 Portfolio in Review
As of Q2 2023, HighVista Strategies held 163 positions worth $219M, up 78% from $123M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
HighVista Strategies deployed $80.7M of net new capital in Q2 2023, opening 55 new positions and adding to 48 existing holdings. Its largest new stake was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 67% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $1.75M trimmed.
- HighVista Strategies's largest Q2 2023 buy was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
- HighVista Strategies added most to Invesco DB Commodity Index Tracking Fund in Q2 2023, an estimated $32.3M increase.
- HighVista Strategies's biggest Q2 2023 reduction was Travere Therapeutics, cutting an estimated $1.75M.
- HighVista Strategies fully exited iShares Russell 1000 Value ETF in Q2 2023, selling an estimated $4.25M.
- HighVista Strategies's ten largest holdings make up 34% of its $219M portfolio in Q2 2023.
- HighVista Strategies opened 55 new positions and closed 29 in Q2 2023.
- HighVista Strategies's portfolio value rose 78% quarter-over-quarter to $219M.
Based on HighVista Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.